Trial record 4 of 7 for:    stx209 and fragile x syndrome

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (Harbor-C)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01325220
Recruitment Status : Completed
First Posted : March 29, 2011
Last Update Posted : July 31, 2013
Information provided by (Responsible Party):
Seaside Therapeutics, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : June 2013
  Study Completion Date : No date given